Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2003
11/13/2003CA2485086A1 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes
11/13/2003CA2484994A1 Peptide antagonists of tgf-beta family members and therapeutic uses thereof
11/13/2003CA2484976A1 Method of inhibiting angiogenesis
11/13/2003CA2484551A1 Smart pro-drugs of serine protease inhibitors
11/13/2003CA2484538A1 Vectors with modified protease-dependent tropism
11/13/2003CA2484425A1 Fusions of cytokines and tumor targeting proteins
11/13/2003CA2484420A1 Antibodies specific for human cd22 and their therapeutic and diagnostic uses
11/13/2003CA2484396A1 Method for control of depression using c terminal growth hormone (gh) fragment
11/13/2003CA2484251A1 Materials and methods for inhibition of respiratory syncytial virus infection
11/13/2003CA2484189A1 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003CA2484155A1 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
11/13/2003CA2483915A1 Vectors having both isoforms of b-hexosaminidase
11/13/2003CA2483909A1 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
11/13/2003CA2483851A1 Methods and compositions for use in homologous recombination
11/13/2003CA2483838A1 Chemically activated carboxypolysaccharides and uses
11/13/2003CA2483778A1 Biomatrix structural containment and fixation systems and methods of use thereof
11/13/2003CA2483653A1 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
11/13/2003CA2483633A1 Composition and method for reducing post-prandial blood glucose
11/13/2003CA2483478A1 Factor vii or viia polypeptide variants
11/13/2003CA2483096A1 Medical device
11/13/2003CA2483084A1 Tyrosine kinase inhibitors
11/13/2003CA2483050A1 Optimization of transgene expression in mammalian cells
11/13/2003CA2483001A1 A combination product comprising melagatran and an anti-arrhythmic oxabispidenes
11/13/2003CA2482967A1 Binary or polynary targeting and uses thereof
11/13/2003CA2482810A1 Teneurin c-terminal associated peptides (tcap) and methods and uses thereof
11/13/2003CA2480777A1 Methods of using cytokine antagonists to treat hiv infection and aids
11/13/2003CA2477985A1 Time-resolved fluorescence assay for the detection of multimeric forms of a-.beta. or other aggregating polypeptides
11/13/2003CA2462879A1 Immunoconjugates for the treatment of tumours
11/12/2003EP1361439A1 Screening for peptides inhibiting PP1c binding to Bcl-2, BCL-Xl and BCL-W proteins
11/12/2003EP1361277A1 Optimization of transgene expression in mammalian cells
11/12/2003EP1361276A1 Pro-urokinase mutants
11/12/2003EP1361273A2 Interleukin-3 (IL-3) multiple mutation polypeptides
11/12/2003EP1361272A1 Neuritin, a neurogene
11/12/2003EP1361271A2 Isolated nonapeptide derived from MAGE-3 gene and presented by HLA-A1, and uses thereof
11/12/2003EP1361269A1 Delivery of gene products via mesangial cells expressing an exogenous gene
11/12/2003EP1361227A2 [5-carboxamide or 5-fluoro]-[2', 3'-unsaturated or 3'-modifield]-pyrimidine nucleosides
11/12/2003EP1361212A1 Peptide derivatives as antithrombotic agents
11/12/2003EP1360965A1 Methods of treating diseases in association with decrease in the expression of aop-1 gene or aop-1 and remedies for the diseases
11/12/2003EP1360964A1 Use of galanin-like peptide
11/12/2003EP1360962A2 Interferon tau composition and methods of use
11/12/2003EP1360961A1 Use of antimicrobial peptides for potentiating the activity of antimicrobial agents
11/12/2003EP1360508A2 Prediction of wound healing by urinary nitrate assay
11/12/2003EP1360504A2 Method for screening compounds for activity in treating an osteoclast related bone disease
11/12/2003EP1360500A2 Methods for selective targeting
11/12/2003EP1360334A1 Methods of using mammalian rnase h and compositions thereof
11/12/2003EP1360311A2 Membrane penetrating peptides and uses thereof
11/12/2003EP1360307A2 Chimeric polypeptides of serum albumin and uses related thereto
11/12/2003EP1360304A2 Enzymes
11/12/2003EP1360302A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/12/2003EP1360299A2 The genome of a bifidobacterium
11/12/2003EP1360296A2 Method for the production of plant seed with modified fibre content and modified seed coat
11/12/2003EP1360295A2 Molecules for desease detection and treatment
11/12/2003EP1360293A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
11/12/2003EP1360292A2 Platelet glycoprotein ib alpha fusion polypeptides and methods of use thereof
11/12/2003EP1360291A2 Human polynucleotides and polypeptides encoded thereby
11/12/2003EP1360290A2 Co-stimulatory molecules
11/12/2003EP1360286A2 Characterization of the gsk-3beta protein and methods of use thereof
11/12/2003EP1360282A2 Degradation and detection of tse infectivity
11/12/2003EP1360281A2 Regulation of human wee1-like serine/threonine protein kinase
11/12/2003EP1360279A2 Novel form of the phgpx protein as a diagnostic marker for male infertility
11/12/2003EP1360208A1 Induvidualized anti-cancer antibodies
11/12/2003EP1360206A2 Isolated human ras-like proteins, nucleic acid molecules encoding them, and uses thereof
11/12/2003EP1360205A1 Angiogenesis-inhibitory tripeptides, compositions and their methods of use
11/12/2003EP1360202A2 Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
11/12/2003EP1360201A1 Modified keratinocyte growth factor (kgf) with reduced immunogenicity
11/12/2003EP1360200A2 Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
11/12/2003EP1360198A2 Novel polypeptides and nucleic acids encoded thereby
11/12/2003EP1360189A1 Formulation of boronic acid compounds
11/12/2003EP1359975A1 Ocular iontophoretic device and method of use
11/12/2003EP1359947A2 A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same
11/12/2003EP1359941A2 Albumin-based drug delivery system and antimicrobial peptides
11/12/2003EP1359936A2 Combined use of factor vii polypeptides and factor viii polypeptides
11/12/2003EP1359935A1 Combined use of factor vii polypeptides and factor ix polypeptides
11/12/2003EP1359934A2 Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
11/12/2003EP1359933A2 Treatment of demyelinating diseases by administering gpe
11/12/2003EP1359932A2 Tip39 polypeptides
11/12/2003EP1359931A1 Prevention of diabetes by administration of gnrh antagonists
11/12/2003EP1359930A2 Novisprins: antimicrobial peptides
11/12/2003EP1359913A1 Thrombin inhibitors
11/12/2003EP1359902A2 Bimodal dry powder formulation for inhalation
11/12/2003EP1359883A2 (psi)(epsilon)rack peptide composition and method for protection against tissue damage due to ischemia
11/12/2003EP1255557B1 Stable, nasally, orally or sublingually applicable pharmaceutical preparation containing desmopressin
11/12/2003EP1210105B1 High density lipoprotein against organ dysfunction following haemorrhagic shock
11/12/2003EP1206444B1 Compounds that inhibit tryptase activity
11/12/2003EP1178819B1 Glutathione reductase for therapy and prophylaxis of aids
11/12/2003EP1146895B1 Thrombopoietin compositions for increasing circulating platelets
11/12/2003EP1140139B1 Use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
11/12/2003EP1137400B1 Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period toff, verfahren zu seiner herstellung und anlage zur durchfuhrung des verfahrens
11/12/2003EP1133308B1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
11/12/2003EP1117677B1 Ligand presenting assembly (lpa), method of preparation and uses thereof
11/12/2003EP1112083B1 Use of an angiogenic factor for the treatment of microvascular angiopathies
11/12/2003EP1109462B1 Method for obtaining avian biological products
11/12/2003EP1051187B1 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
11/12/2003EP1011706B1 USE OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (sRAGE) TO PREVENT ACCELERATED ATHEROSCLEROSIS
11/12/2003EP0988021B1 Keratin fibre oxidation dyeing composition and dyeing method using same
11/12/2003EP0897390B1 Human tumor necrosis factor delta and epsilon
11/12/2003EP0886648B1 Compounds and peptides that bind to the erythropoietin receptor
11/12/2003EP0882067B1 Methods of treating vascular disease with tnf antagonists
11/12/2003EP0871454B1 Phosphorous-containing cysteine and serine protease inhibitors
11/12/2003EP0847272B1 LIPOSOMAL p-ETHOXY OLIGONUCLEOTIDES
1 ... 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 ... 3163